Position in GSK
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$347,649
New position
Shares Held
6,632
first reported quarter
Ownership
0.000%
of shares outstanding
% of Portfolio
0.08%
of 13F equity value
Holder Rank
#560
of 1,033 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026EntryPoint Capital, LLC holds $4,359,430 across 8 Drug Manufacturers - General names. GSK ranks #4 (8.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | GILD |
Gilead Sciences, Inc.
|
13,595 | $1,717,592 | |
| 2 | PFE |
Pfizer Inc
|
40,976 | $986,702 | |
| 3 | BIIB |
Biogen Inc.
|
1,716 | $370,758 | |
| 4 | GSK |
GSK plc
This page
|
6,632 | $347,649 | |
| 5 | NVS |
Novartis AG
|
1,936 | $303,409 | |
| 6 | AMGN |
Amgen Inc
|
654 | $236,826 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
3,499 | $201,612 | |
| 8 | AMRN |
Amarin Corp Plc\Uk
|
12,226 | $194,882 |
All Filings in GSK
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $347,649 | 6,632 | Shares | Sole | 2026-08-13 | |
| No filing history on record for this holder in this stock. | ||||||